Aerovate Therapeutics, Inc. (AVTE)
NASDAQ: AVTE · Real-Time Price · USD
2.530
0.00 (0.00%)
At close: Mar 28, 2025, 4:00 PM
2.509
-0.021 (-0.83%)
After-hours: Mar 28, 2025, 7:10 PM EDT
Company Description
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States.
It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.
The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Aerovate Therapeutics, Inc.
| Country | United States |
| Founded | 2018 |
| IPO Date | Jun 30, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 30 |
| CEO | Timothy Noyes |
Contact Details
Address: 930 Winter Street, Suite M-500 Waltham, Massachusetts 02451 United States | |
| Phone | 617 443 2400 |
| Website | aerovatetx.com |
Stock Details
| Ticker Symbol | AVTE |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $14.00 |
| CIK Code | 0001798749 |
| CUSIP Number | 008064107 |
| ISIN Number | US0080641071 |
| Employer ID | 83-1377888 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Timothy P. Noyes M.B.A. | Chief Executive Officer and Director |
| George A. Eldridge | Chief Financial Officer and Treasurer |
| Dr. Benjamin T. Dake Ph.D. | Founder, President, Chief Operating Officer and Secretary |
| Dr. Ralph W. Niven M.B.A., M.R, Ph.D., Pharm.S | Chief Scientific Officer |
| Hunter Gillies M.D. | Chief Medical Officer |
| Donna Dea | Head of Regulatory Affairs |
| Susan Fischer | Executive Vice President of Development Operations |
| Stephen K. Yu | Senior Vice President of Quality |
| Dr. Sanjeev Khindri | Executive Vice President of Clinical Development |
| Dr. Cheryl Lassen BSc., M.D., MBBCh | Senior Vice President of Clinical Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 27, 2025 | 10-K | Annual Report |
| Mar 26, 2025 | 425 | Filing |
| Mar 25, 2025 | EFFECT | Notice of Effectiveness |
| Mar 25, 2025 | ARS | Filing |
| Mar 25, 2025 | 424B3 | Prospectus |
| Mar 24, 2025 | S-4/A | Filing |
| Mar 14, 2025 | S-4/A | Filing |
| Mar 3, 2025 | 425 | Filing |
| Feb 24, 2025 | S-4/A | Filing |
| Feb 10, 2025 | 425 | Filing |